Stocks and Investing
Stocks and Investing
Wed, May 29, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, May 28, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Eliana Merle Maintained (BBIO) at Strong Buy with Decreased Target to $47 on, May 28th, 2024
Eliana Merle of UBS, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $51 to $47 on, May 28th, 2024.
Eliana has made no other calls on BBIO in the last 4 months.
There are 6 other peers that have a rating on BBIO. Out of the 6 peers that are also analyzing BBIO, 1 agrees with Eliana's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $37 on, Wednesday, January 31st, 2024
These are the ratings of the 5 analyists that currently disagree with Eliana
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $43 on, Monday, May 20th, 2024
- Cory Kasimov of "Evercore ISI Group" Initiated at Buy and Held Target at $50 on, Tuesday, May 14th, 2024
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $45 on, Wednesday, March 20th, 2024
- Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $53 on, Tuesday, March 5th, 2024
- David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $46 on, Friday, February 23rd, 2024
Contributing Sources